CSTONE PHARMA-B (02616) announced that the company has been notified by its Chief Executive Officer, President of R&D, and Executive Director, Dr. Yang Jianxin, that he purchased a total of 976,000 shares on the open market using personal funds between November 2025 and January 2026. Notably, on January 22 and January 23, 2026 alone, he acquired a total of 428,500 shares. This recent purchase continues Dr. Yang's consistent and firm commitment to the company.

Since assuming the role of CEO in August 2022, Dr. Yang has cumulatively purchased a total of 12.477 million shares. Following this latest share acquisition, Dr. Yang's holdings now represent approximately 4.87% of the company's total issued share capital as of the date of this announcement.

Dr. Yang expressed his strong confidence in the company's long-term investment value and core competitive advantages, stating that the increase in his shareholding also signifies his belief in the company's capability to maintain robust operations and achieve high-quality growth in the future. Dr. Yang did not rule out the possibility of further increasing his stake in the company at an appropriate time.

The company's Board of Directors views Dr. Yang's share purchase as a demonstration of his long-term commitment to the company and his full confidence in its future business prospects.